Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20299275 | 0.92 | CYP2D6 (0.60) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL20299276 | 0.92 | CYP2D6 (0.60) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL196226 | 0.89 | CYP2D6 (0.67) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL31047955 | 0.88 | CYP2D6 (0.67) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL28414380 | 0.86 | CYP2D6 (0.64) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL20595058 | 0.86 | CYP2D6 (0.64) | CYP2D6CYP1A2POLBLMNAALDH1A1 | |
| SCHEMBL28683597 | 0.85 | CYP2D6 (0.55) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL9852971 | 0.85 | CYP2D6 (0.62) | CYP2D6POLBLMNAALDH1A1KMT2A | |
| SCHEMBL15904033 | 0.85 | CYP2D6 (0.62) | CYP2D6CYP1A2POLBLMNANPC1 | |
| SCHEMBL15940656 | 0.84 | CYP2D6 (0.61) | CYP2D6CYP1A2POLBLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333587-B | Substituted pyrimidine-2, 4 (1H, 3H) -dione derivatives and uses thereof | 东莞市东阳光新药研发有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111333587-A | Substituted pyrimidine-2, 4(1H,3H) -dione derivatives and uses thereof | 东莞市东阳光新药研发有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9629843-B2 | MTOR modulators and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629843-B2 | MTOR modulators and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-25 | — | — | US | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160000789-A1 | MTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-01-07 | — | — | US | disclosed |
| EP-2313414-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20110224223-A1 | MTOR Modulators and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224223-A1 | MTOR Modulators and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006072-A2 | MTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000789-A1 | MTOR MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | CYP2D6 4679/4885CYP1A2 4868/4885POLB 3273/4885 |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | CYP2D6 4401/4885CYP1A2 4627/4885POLB 2650/4885 |
| US-20110224223-A1 | MTOR Modulators and Uses Thereof | MTOR, RPTOR, RICTOR | CYP2D6 4679/4885CYP1A2 4868/4885POLB 3273/4885 |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | CYP2D6 4401/4885CYP1A2 4627/4885POLB 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.